All In Biotech

NDA 210598 · Mylan Ireland LTD

Yupelri

Revefenacin · Inhalation · Anticholinergic

Novel

Last checked: Nov 19, 2026Latest source record: May 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 9, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

20

6 Phase 3, 1 recruiting

FAERS reports

921

519 serious, 77 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 3, 2022.

YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) .

Mechanism: Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 9, 2018 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • YUPELRI · REVEFENACIN 175MCG/3ML · SOLUTION, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Revefenacin" as an intervention, any sponsor and status, largest first.

All 20 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea240
  • cough68
  • headache60
  • fatigue58
  • death50
  • pneumonia49
  • chronic obstructive pulmonary disease48
  • drug ineffective47
  • nausea47
  • dizziness43
  • off label use41
  • diarrhoea40

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
201978
202092
202181
202260
2023109
202480
2025191
2026229

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Yupelri (Revefenacin)

2024 spending

$7.2M

Beneficiaries

1,636

5,673 claims

Per beneficiary

$4,418

$16.81 per unit

View as table
YearSpending
2020$2,351,014
2021$1,567,644
2022$2,154,000
2023$4,401,830
2024$7,228,259

Part B: Yupelri (Revefenacin) · HCPCS J7677

2024 spending

$175M

Beneficiaries

29,240

175,788 claims

Per beneficiary

$5,987

2024 ASP limit $0.19 per unit

View as table
YearSpending
2020$123,252,921
2021$138,164,555
2022$155,971,190
2023$172,733,427
2024$175,048,323

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Mylan Ireland LTD

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.